{
    "clinical_study": {
        "@rank": "21619", 
        "arm_group": {
            "arm_group_label": "rituximab", 
            "arm_group_type": "Experimental", 
            "description": "Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle)."
        }, 
        "brief_summary": {
            "textblock": "There is now substantial evidence that B cells are recruited into prostate cancers by CXCL13\n      released by the tumor cells. B cells release lymphotoxin which drives malignant cell\n      proliferation through the NFkB pathway. This is a pilot trial in 18 patients to determine\n      whether depletion of B cells by rituximab will result in a decrease in the extent of B cell\n      infiltration of the prostatic cancer. The extent of infiltration in the diagnostic biopsy\n      will be compared to that in the prostatectomy samples following administration of 4 weekly\n      doses of rituximab."
        }, 
        "brief_title": "Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is an open label, single institution, pilot study of rituximab neoadjuvant therapy in\n      patients with high risk prostate cancer scheduled to undergo radical prostatectomy. Prior to\n      prostatectomy, patients will receive one treatment cycle (28 days) of rituximab 375 mg/m2\n      intravenously once weekly.  Patients will be scheduled to undergo radical prostatectomy\n      within two weeks of completing study treatment. Tissue from prostatectomy will be used for\n      immunohistochemistry (IHC) staining of pharmacodynamic markers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to understand and provide written informed consent.\n\n          -  Patient has EITHER:\n\n               -  A Kattan nomogram predicted probability of being disease free 5 years after\n                  surgery of < 60%, OR\n\n               -  A Gleason sum \u2265 8.\n\n          -  Indicated for radical prostatectomy.\n\n        Note: candidates for radical prostatectomy are still eligible even if they have a history\n        of deep venous thrombosis, pulmonary embolism, and/or cerebrovascular accident or\n        currently requiring systemic anticoagulation.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (Appendix A).\n\n          -  Males aged \u2265 18 years.\n\n          -  Adequate organ function as defined below measured within 21 days of study entry:\n\n          -  Hematology:\n\n               -  Absolute Neutrophil Count (ANC) \u2265 1.5 x 109/L\n\n               -  Platelet count \u2265 100 x 109/L\n\n               -  Hemoglobin \u2265 9.0 g/dL\n\n               -  White blood cell (WBC) count \u2265 3.0 x 109/L\n\n          -  Biochemistry:\n\n               -  Aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT)\n                  and alanine transaminase/serum glutamate pyruvate transaminase (ALT/SGPT) \u2264 2 x\n                  institution's upper limit of normal (ULN)\n\n               -  Total bilirubin <1.5 times ULN\n\n               -  Serum creatinine  and blood urea nitrogen (BUN)<1.5 times ULN\n\n               -  Na, K Cl, carbon dioxide (CO2), Ca, phosphate (PO4) within institutional  limits\n\n          -  Available prostate biopsy specimen which is evaluable for B lymphocyte count.\n\n        Exclusion Criteria:\n\n          -  Received prior treatment for prostatic adenocarcinoma including prior surgery\n             (excluding TURP), radiation therapy, or chemotherapy.\n\n          -  Current or past use of investigational agents within 4 weeks of study enrollment.\n\n          -  Evidence of metastatic disease on cross sectional imaging or bone scan.\n\n          -  History of hepatitis B or C, hepatitis immunodeficiency virus (HIV), tuberculosis or\n             a chronic infection of any type.\n\n          -  Positive test results for chronic hepatitis B infection (defined as positive HBsAg\n             serology).\n\n          -  Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology\n             testing)."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01804712", 
            "org_study_id": "121451"
        }, 
        "intervention": {
            "arm_group_label": "rituximab", 
            "description": "Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).", 
            "intervention_name": "rituximab", 
            "intervention_type": "Drug", 
            "other_name": "Rituxan"
        }, 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Prostate", 
            "Cancer", 
            "Castration-resistant", 
            "Rituximab", 
            "neoadjuvant", 
            "Rituxan"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "La Jolla", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92093-0698"
                }, 
                "name": "Moores UCSD Cancer Center"
            }, 
            "investigator": {
                "last_name": "Stephen Howell, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study of Rituximab Neoadjuvant Therapy in Patients With High Risk Prostate Cancer Scheduled to Undergo Radical Prostatectomy", 
        "overall_contact": {
            "email": "llow@ucsd.edu", 
            "last_name": "Larissa Low", 
            "phone": "858-822-5223"
        }, 
        "overall_contact_backup": {
            "email": "aaraneta@ucsd.edu", 
            "last_name": "Arlene Aaraneta", 
            "phone": "858-822-5374"
        }, 
        "overall_official": {
            "affiliation": "University of California Medical Center", 
            "last_name": "Stephen Howell, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Histologic response rate after one cycle of rituximab", 
            "safety_issue": "No", 
            "time_frame": "1 treatment cycle (28 days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01804712"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, San Diego", 
            "investigator_full_name": "Stephen Howell, M.D.", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in prostate-specific antigen (PSA)", 
                "safety_issue": "No", 
                "time_frame": "from Day 1 to Day 29"
            }, 
            {
                "measure": "Change in peripheral blood B cell number", 
                "safety_issue": "No", 
                "time_frame": "from Day 1 to Day 29"
            }, 
            {
                "measure": "Change in serum CXCL13 level", 
                "safety_issue": "No", 
                "time_frame": "from Day 1 to Day 29"
            }
        ], 
        "source": "University of California, San Diego", 
        "sponsors": {
            "collaborator": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Stephen Howell, M.D.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}